We performed a retrospective analysis of muscle strength testing obtained following sibling or unrelated donor hematopoietic stem cell transplant (HSCT) between 1 January 1999 and 31 December 2003 in a cohort of 44 subjects at Tufts-New England Medical Center. Maximal inspiratory pressure (PI max ) was p80% predicted in 52% of subjects and p60% predicted in 20% of subjects; maximal expiratory pressure (PE max ) was p80% predicted in 88% of subjects and p60% predicted in 74% of subjects. Patients with a PI max p60% predicted spent significantly longer time in hospital following HSCT compared with subjects with PI max 60% predicted. Grip strength (n ¼ 32) was reduced to p80% predicted in 75% of subjects and p60% predicted in 47% of subjects following HSCT. Analysis of paired measurements obtained before and after HSCT in 20 of the 44 subjects (45%) showed significant reduction in both PI max and PE max between the two measures. Respiratory and skeletal muscle weakness is present in a significant percentage of subjects undergoing pulmonary function testing in the post-HSCT period, and may contribute to pulmonary morbidity in subjects with pulmonary complications of HSCT.
We performed a retrospective analysis of muscle strength testing obtained following sibling or unrelated donor hematopoietic stem cell transplant (HSCT) between 1 January 1999 and 31 December 2003 in a cohort of 44 subjects at Tufts-New England Medical Center. Maximal inspiratory pressure (PI max ) was p80% predicted in 52% of subjects and p60% predicted in 20% of subjects; maximal expiratory pressure (PE max ) was p80% predicted in 88% of subjects and p60% predicted in 74% of subjects. Patients with a PI max p60% predicted spent significantly longer time in hospital following HSCT compared with subjects with PI max 60% predicted. Grip strength (n ¼ 32) was reduced to p80% predicted in 75% of subjects and p60% predicted in 47% of subjects following HSCT. Analysis of paired measurements obtained before and after HSCT in 20 of the 44 subjects (45%) showed significant reduction in both PI max and PE max between the two measures. Respiratory and skeletal muscle weakness is present in a significant percentage of subjects undergoing pulmonary function testing in the post-HSCT period, and may contribute toIntroduction Impaired respiratory and skeletal muscle function can contribute to general and pulmonary morbidity in subjects undergoing hematopoietic stem cell transplant (HSCT). We recently reported clinically significant respiratory and skeletal muscle weakness in 30% of subjects before sibling or unrelated donor HSCT. 1 To estimate the prevalence of respiratory and skeletal muscle weakness in subjects who have survived HSCT, we performed an analysis of all respiratory and skeletal muscle strength data obtained from subjects undergoing pulmonary function testing (PFT) following HSCT over a 5-year period. In a subset of subjects, data obtained before HSCT were available for comparison.
Methods
Subjects were included in the study using the following selection criteria: undergoing HSCT (sibling or unrelated donor) at Tufts-New England Medical Center (T-NEMC), age 18 years or older and undergoing both PFT and testing of muscle strength following HSCT on at least one occasion at T-NEMC between 1 January 1999 and 31 December 2003. Of the 178 subjects undergoing HSCT in the time period, 44 (25%) were identified by combining the databases available in the PFT laboratory and the HSCT unit. In a subgroup of 20 (45%) of these 44 subjects, measures of muscle strength had also been performed in the pre-HSCT period and were available for comparison with the post-HSCT data. An evaluation of skeletal and respiratory muscle strength had been added to routine PFT as a result of our experience with severe skeletal muscle weakness occurring following HSCT in the posttransplant period. 2 The additional testing of respiratory and skeletal muscle function was considered part of the clinical management of the patient undergoing HSCT starting in January 2002. The Institutional Review Board at T-NEMC approved this analysis of de-identified data, without obtaining informed consent from the subjects.
Demographic, clinical and diagnostic data
The following data were extracted from the medical records of each patient: age, sex, ethnicity, body mass index, underlying hematological diagnosis, date of HSCT, days elapsed between PFT performed before and following HSCT, days elapsed from HSCT to PFT following HSCT, presence or absence of chronic GVHD, number of days spent hospitalized following HSCT and before undergoing PFT following HSCT, and the use of corticosteroid in the three months before undergoing PFT post-PFT.
Conditioning regimen transplantation procedure and GVHD prophylaxis All regimens used for patients undergoing sibling or unrelated donor HSCT have been described previously. [3] [4] [5] PFTs Spirometry, lung volumes and diffusing capacity were all measured using a Sensormedic Vmax 229 system according to the guidelines of the American Thoracic Society (ATS) 6 as previously described. 1 Skeletal muscle (grip) strength Grip strength (GS) was used as a measure of skeletal muscle strength and was measured using a hand dynamometer in the dominant hand with the elbow at 901 flexion and with the arm and wrist in neutral position (JAMAR, JA Preston Corporation, Clifton, NJ, USA), 7 as previously described. 1 Submaximal exercise capacity The 6 minute walk test (6 MWT) was measured in accordance with published ATS guidelines.
8 Predicted values for 6 MWT distance were calculated for each subject using the variables height, age and weight as previously reported. 9 Respiratory muscle force The maximal inspiratory pressure (PI max ) and maximal expiratory pressure (PE max ) were measured according to a modification of the Black and Hyatt method 10 as previously described.
1 Abnormal values were classified as less than 80% predicted or less than 60% predicted, as these thresholds have been shown to have some correlation with dyspnea scores.
11
Statistical analysis All data were entered into an Excel spreadsheet and deidentified according to Federal guidelines. Data are presented as means ± s.d. Data not normally distributed were expressed as median with interquartile ranges. Univariate comparisons were performed using paired (in those subjects with measurements available both pre-and post-HSCT) or the unpaired Student's t-test (quantitative variables), w 2 -test (categorical variables) or the Wilcoxon rank-sum test (quantitative variable not normally distributed). All statistical analyses were performed using the SAS statistical package version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results

Clinical data results
The demographic and clinical data for the 44 subjects are shown in Table 1 . Eighty-one percent of subjects received a sibling HSCT, with 20% receiving HSCT from an unrelated donor. The median time elapsed from the date of HSCT to the date of PFT and muscle strength testing following HSCT was 647 days. Twenty-six (58%) of the subjects developed chronic GVHD following HSCT. The average time a subject spent in hospital following HSCT was 49 ± 25 days.
Respiratory and skeletal muscle strength post-HSCT The data obtained for PI max and PE max in the 44 subjects following HSCT are shown in Table 2 . Of note, the mean values for PI max and PE max were reduced to 80 ± 26 and 53±20, respectively. Large percentages of subjects had values for PI max and PE max that were less then 80 and 60% of predicted values. Subjects with a PI max p59% predicted (n ¼ 9) spent significantly more days in the hospital following HSCT compared with those subjects with PI max values X60% (n ¼ 35) (PI max p59% predicted: 52 days (48-74) versus PI max X60% predicted: 37 days (28-56), P ¼ 0.02). (Data are presented as medians, 25-75th percentile.) For this analysis, we considered a threshold of PI max 60% predicted to be clinically meaningful based on our prior analysis of respiratory muscle strength in subjects before HSCT. 1 There were no significant differences noted between the two groups for time elapsed in days from HSCT to PFT following HSCT, presence of chronic GVHD or the use of corticosteroid in the three months before undergoing PFT post-PFT (data not shown).
The mean GS was significantly reduced in the 32/44 (73%) subjects who underwent testing, and only 25% of subjects had values in the normal range. Six MWT The 6 MWT was performed on 21/44 (48%) subjects post-HSCT and the mean value was reduced to 69±18% predicted. The majority of subjects undergoing the 6 MWT following HSCT had values that were less than 80% predicted.
Comparison of measurements in subjects with paired measures before and after HSCT Paired measurements of respiratory muscle strength performed before and after HSCT were available in 20/44 (45%) of the subjects. Paired measures of GS and 6 MWT were also available for analysis in 9/44 (20%) and 7/44 (16%) subjects, respectively. The analysis of the available paired data are shown in Table 3 and the individual data points for PI max and PE max are shown in scatterplots in Figures 1 and 2 , respectively. In these subsets of subjects, a significant reduction in PI max , PE max and GS was observed from the pre-HSCT evaluation to the post-HSCT evaluation using a paired analysis ( Table 3 ). The scatterplots (Figures 1 and 2) show that the majority of the subgroup experienced a reduction in PI max and PE max over the course of the HSCT (values fall to the right of the diagonal). However, it is worth noting that four subjects had significant improvement in PI max and three subjects had significant improvement in PE max following HSCT (values fall to the left of the respective diagonals). In the majority of subjects, paired testing was performed in less than 600 days. There was no significant reduction observed in the 6 MWT over the course of the HSCT in the seven subjects with paired measurements.
Discussion
This retrospective study demonstrates significant respiratory and skeletal muscle weakness in subjects undergoing PFT following an HSCT. In over 50% of subjects, we observed mild reductions in both PI max and PE max . A moderate reduction in PI max was seen in 20% of subjects, with 74% of subjects having a moderate reduction in PE max . We also observed significant reductions in skeletal muscle strength in 47% of subjects. In a subset of subjects, a reduction in submaximal exercise capacity was also observed.
Respiratory muscle weakness has been described in a wide range of diseases. 12 Abnormalities in PFT have been detected following HSCT, 13 but there has not been a systematic analysis of respiratory or skeletal muscle strength following HSCT. The literature to date is comprised mainly of small case series and case reports. 2, [14] [15] [16] [17] [18] [19] In a previous study, we demonstrated respiratory and skeletal muscle weakness in up to 30% of subjects 1 before undergoing HSCT. This study extends these observations and demonstrates that significant respiratory and skeletal muscle weakness can still be detected in those Table 2 Respiratory and skeletal muscle strength and submaximal exercise testing in subjects following HSCT subjects undergoing PFT following HSCT. Furthermore, we were able to obtain paired measurements of respiratory muscle strength in a subset of 20 subjects before and after HSCT, and analysis of these data demonstrated a significant reduction in both PI max and PE max following HSCT. Within this subset, a small number of subjects showed an increase in respiratory muscle strength following HSCT. Thus, some subjects can recover sufficiently following HSCT to regain muscle function. Patients undergoing HSCT are exposed to a number of risk factors for muscle damage, including multiple courses of chemotherapy, TBI, high-dose corticosteroids, loss of muscle strength due to treatment-related immobility, transplant-related muscle damage and GVHD-related muscle damage. 20 Oxidative stress from chemotherapy and radiation treatments, 21 along with iron overload from multiple blood transfusions, 22 may contribute to muscle dysfunction 23 through excessive production of reactive oxygen species.
We have recently demonstrated that subjects before HSCT have lower plasma concentrations of glutathione peroxidase, an important component of the circulating antioxidant system, compared with controls. 24 Thus, increased reactive oxygen species production along with an impaired antioxidant system may contribute to muscle weakness in the post-HSCT period.
Over 85% of subjects in this study had received corticosteroids in the three months before undergoing PFT following HSCT. We were unable to show significant association between corticosteroid use and the severity of inspiratory muscle strength due, in part, to the high prevalence of corticosteroid use in the study population, but it is likely that corticosteroid use contributed to the observed skeletal and respiratory muscle weakness in subjects following HSCT. Corticosteroid use has been shown to correlate with reductions in PI max and PE max , 25 and corticosteroid-related myopathy has been reported in many settings, including solid organ transplant recipients. 26 Glucocorticoid-related myopathy is considered to result from decreased release of insulin growth factor, increased myofibril catabolism, impaired glycolysis 12 and activation of the ubiquitin-proteosome pathway. 27 Immobility due to fatigue from conditioning treatment, comorbid diseases and the need for isolation precautions for sterility occurs in subjects undergoing HSCT and has been shown to increase steroid-related myopathy. 28 Using the number of days spent hospitalized following HSCT as a surrogate marker of transplant-related immobility, the data did demonstrate significant association between the number of days spent in hospital and the severity of respiratory muscle weakness. This suggests that prolonged immobility may have contributed to the observed muscle weakness following HSCT. Thus, the observed muscle weakness may be more likely related to complications of HSCT rather than the process of HSCT itself.
Bronchiolitis obliterans, the idiopathic pneumonia syndrome, diffuse alveolar hemorrhage and delayed pulmonary toxicity syndrome are likely extreme forms of chemotherapy-related lung injury. To date, respiratory and skeletal muscle weakness has not been a well-defined noninfectious pulmonary complication of HSCT. We believe that the presence of reduced inspiratory muscle strength, expiratory muscle strength and skeletal muscle strength supports a global reduction in muscle function in some patients following HSCT. Reduced muscle strength may contribute to pulmonary morbidity especially in patients with pulmonary complications of HSCT such as airflow obstruction or interstitial lung disease. Our observations add to the available data in organ transplant literature that respiratory and skeletal muscle weakness can be a significant clinical finding in subjects following transplantation in general.
Specific inspiratory muscle training has been shown to prevent pulmonary complications and improve pulmonary function in certain populations. 29 Additional studies of both cancer subjects and of those undergoing HSCT have demonstrated the benefits of an aerobic exercise program in subjects with fatigue and weakness. 30 This study has some significant limitations, including the retrospective design, small sample size and referral bias. The range of time elapsed from HSCT to performance of PFTs and muscle testing following HSCT is large and makes difficult the interpretation of the observed reductions in strength.
In summary, we have demonstrated significant respiratory and skeletal muscle weakness in a cohort of subjects undergoing PFT following HSCT. The musculoskeletal weakness is likely due to accumulated muscle damage occurring before HSCT, 1 along with additional damage accrued in the post-HSCT period. Measurements of respiratory and skeletal muscle strength should be considered in HSCT subjects undergoing a pulmonary evaluation in the post-HSCT period.
